CSIMarket
 
Spruce Biosciences Inc   (SPRB)
Other Ticker:  
 
 
Price: $0.8080 $0.00 -0.321%
Day's High: $0.9 Week Perf: -84.22 %
Day's Low: $ 0.80 30 Day Perf: -83.51 %
Volume (M): 7,528 52 Wk High: $ 5.95
Volume (M$): $ 6,082 52 Wk Avg: $2.40
Open: $0.84 52 Wk Low: $0.78



 Market Capitalization (Millions $) 33
 Shares Outstanding (Millions) 41
 Employees -
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) 77
 Capital Exp. (TTM) (Millions $) 0

Spruce Biosciences Inc
Spruce Biosciences Inc is a pharmaceutical company that is focused on developing and commercializing novel therapies for rare endocrine disorders. The company is dedicated to addressing unmet medical needs and improving the lives of patients with these disorders. Spruce Biosciences is actively engaged in research and development activities to advance its product pipeline and bring innovative treatments to market.


   Company Address: 611 Gateway Boulevard South San Francisco 94080 CA
   Company Phone Number: 655-4168   Stock Exchange / Ticker: NASDAQ SPRB
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Spruce Biosciences Inc

Spruce Biosciences Inc Generates Remarkable Third Quarter Revenue of $3.073 Million in Rapid Growth Phase

The Stock Market Soars as Major Pharmaceutical Preparations Company Reports Impressive Earnings
In the fast-paced and ever-evolving world of the stock market, it is always a delight to come across a company that sets itself apart from the rest. The Major Pharmaceutical Preparations company has shown its prowess and ability to generate substantial revenue with an impressive $3.073 million in the third quarter of the 2023 earnings season. This remarkable achievement has left investors and market analysts astounded.
The company's success can be attributed to several key factors. First and foremost, their commitment to groundbreaking research and development has resulted in the creation of innovative pharmaceutical products that meet the pressing needs of today's healthcare industry. These cutting-edge solutions have not only gained significant market share but have also positively impacted the lives of countless individuals around the globe.

Spruce Biosciences Inc

Spruce Biosciences Inc Records Impressive Revenue of $2.165 Million Amid Concerns of Net Deficit in Q2 2023

Spruce Biosciences Inc, a major pharmaceutical preparations company, recently announced its financial performance for the second quarter of 2023. Despite reporting a net deficit of $-12.824 million, which is larger than the previous year's $-11.872 million, the company's revenue stood at an impressive $2.165 million.
These financial figures may raise concerns among investors, as the net deficit has exceeded the previous year's losses. However, it is important to note that this is just a snapshot of the company's financial performance for a specific period.

Spruce Biosciences Inc

Spruce Biosciences Inc Reports Revenue of $1.964 Million for Fiscal Year Ending March 31, 2023, Despite Increasing Net Deficit

Spruce Biosciences Inc, a California based biopharmaceutical company, has recently reported its financial results for the fiscal span ending March 31, 2023. The company announced a revenue of $1.964 million for the period. However, the net deficit for the same period stands at $-12.791 million, which is larger than the deficit of $-11.762 million reported in the previous year.
Spruce Biosciences Inc, founded in 2014, primarily focuses on developing treatments for endocrine disorders in children and adults. Endocrine disorders are hormonal imbalances that require specialized treatment and can potentially cause long term health issues if not addressed adequately.






 

Spruce Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com